Note: Ingredients listed on restricted chemical lists
EC/CAS
7631-86-9
Name of the chemical
Silver adsorbed on silicon dioxide
Concentration
N/A
EC/CAS
63-42-3
Name of the chemical
Lactose C12H22O11
Concentration
N/A
EC/CAS
9004-64-2
Name of the chemical
hydroxypropylcellulose
Concentration
N/A
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
EC/CAS
8004-92-0
Name of the chemical
1H-Indene-1,3(2H)-dione, 2-(2-quinolinyl)-, sulfonated, sodium salts (CI 47005) (35), (36)
Concentration
N/A
EC/CAS
209-150-3
Name of the chemical
Aluminium, zinc, magnesium and calcium stearates
Concentration
N/A
EC/CAS
418-260-2
Name of the chemical
Kalium-1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-yliden)-1-propenyl]pyrazol-5-olat; [Gehalt an N,N-Dimethylformamid (EG-Nr. 200-679-5) ≥ 0,5 %] (790/2009)
Concentration
N/A
EC/CAS
212-728-8
Name of the chemical
Disodium 5,5'-(2-(1,3-dihydro-3-oxo-2H-indazol-2-ylidene)-1,2-dihydro-3H-indol-3-one)disulphonate
Concentration
N/A
EC/CAS
200-559-2
Name of the chemical
Lactose C12H22O11
Concentration
N/A
EC/CAS
231-791-2
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
EC/CAS
220-491-7
Name of the chemical
Disodium 6-hydroxy-5-[(4-sulphonatophenyl)azo]naphthalene-2-sulphonate and its insoluble barium, strontium and zirconium lakes, salts and pigments
Concentration
N/A
General Information
Revision date
2007-11-26
Product name
OGEN; OGENEST; HARMOGEN; GENORAL
Product Synonyms
Estrone Piperazine Sulfate
Chemical name
Synthetic estrogen
Icons in SDS
Company Information
company name
Pfizer Inc
e-mail address of the competent person responsible for the Safety Data Sheet
pfizer-MSDS@pfizer.com
GHS Information
Signal word
WARNING
Section 2
SECTION 2: Hazards identification
Appearance: Yellow, Peach, or Blue Tablets, varying in color depending on strength
Signal word
WARNING
Hazard statements
May cause cancer. May damage fertility or the unborn child.
Additional information
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on developing fetus. Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and amenorrhea). Known Clinical Effects: Clinical use of estrogens has resulted in breast changes (enlargement, tenderness, and secretion), along with effects on the genitourinary (changes in vaginal bleeding), and GI systems. Effects on the skin, eyes, and CNS have also been reported. Clinical use has caused clotting abnormalities which may lead to stroke, heart attack, and pulmonary embolism. EU Indication of danger: Carcinogenic: Category 1 Toxic to reproduction: Category 1 EU Hazard Symbols: EU Risk Phrases: R45 - May cause cancer. R60 - May impair fertility. R61 - May cause harm to the unborn child. Australian Hazard Classification
Hazardous Ingredients
Non-Dangerous Goods (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
